Epidemiology of the revised European-American lymphoma classification subtypes

Epidemiologic Reviews

Volumn 20, Issue 2, 1998, Pages 187-203

  Herrinton, Lisa J ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; IONIZING RADIATION; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; LYMPHOCYTOMA; LYMPHOMA; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RADIATION EXPOSURE; REVIEW; SEX DIFFERENCE; SEZARY SYNDROME;

EID: 0032425994     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017980     Document Type: Review

References (134)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.
2. Berard CW, Hutchison RE. The problem of classifying lymphomas: an orderly prescription for progress. Ann Oncol 1997;8(Suppl 2):S3-9.
3. Sreenan JJ, Tubbs RR. The influence of immunology and genetics on lymphoma classification: a historical perspective. Cancer Invest 1996;14:572-88.
4. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a Working Formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49:2112-35.
5. Percy C, O'Conor G, Ries LG, et al. Non-Hodgkin's lymphoma: application of the International Classification of Diseases for Oncology (ICD-O) to the Working Formulation. Cancer 1984;54:1435-8.
6. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988;1:292-3.
7. Pittaluga S, Bijnens L, Teodorovic I, et al. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood 1996;87:4358-67.
8. Kosary CL, Ries LAG, Miller BA, et al. SEER cancer statistics review, 1973-1992. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1996.
9. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992;52(19 Suppl):5432s-40s.
10. Newell GR, Cabanillas FG, Hagemeister FJ, et al. Incidence of lymphoma in the US classified by the Working Formulation. Cancer 1987;59:857-61.
11. Linet MS, Cartwright RA. The leukemias. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. New York, NY: Oxford University Press, 1996:841-92.
12. Parker DM, Muir CS, Whelan SL, et al. Cancer incidence in five continents. Vol VI. Lyon, France: International Agency for Research on Cancer, 1993. (IARC scientific publications no. 120).
13. Herrinton LJ, Goldoft M, Schwartz SM, et al. The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants. Cancer Causes Control 1996;7:224-30.
14. Mazzaro C, Zagonel V, Monfardini S, et al. Hepatitis C virus and non-Hodgkin's lymphomas. Br J Haematol 1996;94: 544-50.
15. Brandt L, Brandt J, Olsson H, et al. Blood transfusion as a risk factor for non-Hodgkin lymphoma. Br J Cancer 1996; 73:1148-51.
16. Blair A, Linos A, Stewart PA, et al. Comments on occupational and environmental factors in the origin of non-Hodgkin's lymphoma. Cancer Res 1992;52(19 Suppl): 5501s-2s.
17. Cantor KP, Blair A, Everett G, et al. Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota. Cancer Res 1992;52:2447-55.
18. Hardell L, Eriksson M, Degerman A. Exposure to phenoxy-acetic acids, chlorophenols, or organic solvents in relation to histopathology, stage, and anatomical localization of non-Hodgkin's lymphoma. Cancer Res 1994;54:2386-9.
19. Frizzera G. Recent progress in lymphoma classification. Curr Opin Oncol 1997;9:392-402.
20. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993;82:3148-50.
21. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998;82:1078-81.
22. Linet MS, Humphrey RL, Mehl ES, et al. A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia 1993;7:1363-9.
23. Pasqualetti P, Casale R. Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Biomed Pharmacother 1997;51:74-8.
24. Kyle RA. "Benign" monoclonal gammopathy - after 20 to 25 years of follow-up. Mayo Clin Proc 1993;68:26-36.
25. Izumi T, Sasaki R, Tsunoda S, et al. B cell malignancy and hepatitis C virus infection. Leukemia 1997;11(Suppl 3): 516-18.
26. Mangia A, Clemente R, Musto P, et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia 1996;10:1209-13.
27. Yanagihara ET, Blaisdell RK, Hayashi T, et al. Malignant lymphoma in Hawaii-Japanese: a retrospective morphologic survey. Hematol Oncol 1989;7:219-32.
28. Kadin ME, Berard CW, Nanba K, et al. Lymphoproliferative diseases in Japan and western countries: proceedings of the United States-Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. Hum Pathol 1983;14:745-72.
29. Cantor KP, Blair A, Everett G, et al. Hair dye use and risk of leukemia and lymphoma. Am J Public Health 1988;78: 570-1.
30. Zahm SH, Blair A. Pesticides and non-Hodgkin's lymphoma. Cancer Res 1992;52(19 Suppl):5485s-8s.
31. Grodstein F, Hennekens CH, Colditz GA, et al. A prospective study of permanent hair dye use and hematopoietic cancer. J Natl Cancer Inst 1994;86:1466-70.
32. Linos A, Blair A, Cantor KP, et al. Leukemia and non-Hodgkin's lymphoma among embalmers and funeral directors. (Letter). J Natl Cancer Inst 1990;82:66.
33. Scherr PA, Hutchison GB, Neiman RS. Non-Hodgkin's lymphoma and occupational exposure. Cancer Res 1992;52(19 Suppl):5503s-9s.
34. Tatham L, Tolbert P, Kjeldsberg C. Occupational risk factors for subgroups of non-Hodgkin's lymphoma. Epidemiology 1997;8:551-8.
35. Herrinton LJ, Friedman GD. Cigarette smoking and risk of non-Hodgkin's lymphoma subtypes. Cancer Epidemiol Biomarkers Prev 1998;7:25-8.
36. Zahm SH, Weisenburger DD, Holmes FF, et al. Tobacco and non-Hodgkin's lymphoma: combined analysis of three case-control studies (United States). Cancer Causes Control 1997; 8:159-66.
37. De Wolf-Peeters C, Pittaluga S. Further considerations on the Revised European-American Lymphoma classification. Curr Opin Oncol 1996;8:366-70.
38. Hernandez JA, Olive A, Ribera JM, et al. Probability of the development of non-Hodgkin's lymphoma in primary Sjogren's syndrome. (Letter). Scand J Rheumatol 1996;25: 396-7.
39. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766-75.
40. Anaya JM, McGuff HS, Banks PM, et al. Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin Arthritis Rheum 1996;25:337-46.
41. IARC monograph on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon, France: International Agency for Research on Cancer, 1994. (IARC scientific publications no. 61).
42. Parsonnet J, Hansen S, Rodriquez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330:1267-71.
43. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.
44. Stolte M, Eidt S. Healing gastric MALT lymphomas by eradicating H. pylori? Lancet 1993;342:568.
45. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997;127:423-8.
46. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 1990;50: 3605-9.
47. Clavel J, Hemon D, Mandereau L, et al. Farming, pesticide use and hairy-cell leukemia. Scand J Work Environ Health 1996;22:285-93.
48. Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993; 85:714-17.
49. Clavel J, Mandereau L, Cordier S, et al. Hairy cell leukaemia, occupation, and smoking. Br J Haematol 1995;91: 154-61.
50. Oleske D, Golomb HM, Farber MD, et al. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol 1985;121:675-83.
51. Nordstrom M, Hardell L, Magnusson A, et al. Occupation and occupational exposure to UV light as risk factors for hairy cell leukaemia evaluated in a case-control study. Eur J Cancer Prev 1997;6:467-72.
52. Herrinton LJ, Weiss NS, Olshan AF. Multiple myeloma. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. New York, NY: Oxford University Press, 1996:946-70.
53. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987; 36(suppl 1):1S-15S.
54. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-9.
55. Rabkin CS, Biggar RJ, Horm JW. Increasing incidence of cancers associated with the human immunodeficiency virus epidemic. Int J Cancer 1991;47:692-6.
56. Pallesen G, Hamilton-Dutoit SJ, Zhou X. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. Adv Cancer Res 1993;62:179-239.
57. Swinnen LJ. Transplant immunosuppression-related malignant lymphomas. Cancer Treat Res 1993;66:95-110.
58. Biggar RJ, Rabkin CS. The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr Opin Oncol 1992;4:883-93.
59. Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst 1993;85:1382-97.
60. Rabkin CS. Epidemiology of AIDS-related malignancies. Curr Opin Oncol 1994;6:492-6.
61. Serraino D, Franceschi S, Greco D, et al. AIDS-associated Kaposi's sarcoma and non-Hodgkin's lymphomas reporting in Italy: a linkage study. J Acquir Immune Defic Syndr 1994;7:1202-7.
62. Coté TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997;73:645-50.
63. Roithmann S, Tourani JM, Andrieu JM. AIDS-associated non-Hodgkin lymphoma. (Letter). Lancet 1991;338:884-5.
64. Pedersen C, Gerstoft J, Lundgren JD, et al. HIV-associated lymphoma: histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. Eur J Cancer 1991;27:1416-23.
65. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al. AIDS-related lymphoma: histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 1991;138:149-63.
66. Armenian HK, Hoover DR, Rubb S, et al. Risk factors for non-Hodgkin's lymphomas in acquired immunodeficiency syndrome (AIDS). Am J Epidemiol 1996;143:374-9.
67. Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993;82:619-24.
68. Ballerini P, Gaidano G, Gong JZ, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 1993;81:166-76.
69. Delecluse HJ, Raphael M, Magaud JP, et al. Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. I. Blood 1993;82:552-63.
70. Carbone A, Tirelli U, Gloghini A, et al. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993;11:1674-81.
71. Meeker TC, Shiramizu B, Kaplan L, et al. Evidence for molecular subtypes of HIV-associated lymphoma: division into peripheral monoclonal, polyclonal and central nervous system lymphoma. AIDS 1991;5:669-74.
72. Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993;11:1099-107.
73. Rabkin CS, Hilgartner MW, Hedberg KW, et al. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA 1992;267: 1090-4.
74. Ragni MV, Belle SH, Jaffe RA, et al. Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia. Blood 1993;81:1889-97.
75. Horn PL, DeLorenze GN, Brown SR, et al. Re: "Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS)." (Letter). Am J Epidemiol 1989;130:1069-71.
76. Bernstein L, Levin D, Menck H, et al. AIDS-related secular trends in cancer in Los Angeles County men: a comparison by marital status. Cancer Res 1989;49:466-70.
77. Hessol NA, Katz MH, Liu JY, et al. Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann Intern Med 1992;117:309-11.
78. Ahmed T, Wormser GP, Stahl RE, et al. Malignant lymphomas in a population at risk for acquired immune deficiency syndrome. Cancer 1987;60:719-23.
79. Hoover R, Fraumeni JF Jr. Risk of cancer in renal-transplant recipients. Lancet 1973;2:55-7.
80. Hoover RN. Lymphoma risks in populations with altered immunity - a search for mechanism. Cancer Res 1992;52(19 Suppl):5477s-8s.
81. Kinlen LJ, Sheil AGR, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-6.
82. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-16.
83. Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients: clinical and histological features and immunological phenotype. Transplantation 1982;33:347-51.
84. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323: 1723-8.
85. Raymond E, Tricottet V, Samuel D, et al. Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Cancer 1995;76:1344-51.
86. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981;41:4262-79.
87. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:4253-61.
88. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
89. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72:520-9.
90. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989;321:784-9.
91. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-43.
92. Sigurgeirsson B, Agnarsson BA, Lindelof B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 1994; 308:13-15.
93. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
94. Katusic S, Beard CM, Kurland LT, et al. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985;78:50-5.
95. Hakulinen T, Isomäki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78:29-32.
96. Prior P, Symmons DPM, Hawkins CF, et al. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128-31.
97. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
98. Gridley G, Klippel JH, Hoover RN, et al. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994; 120:35-9.
99. Pettersson T, Pukkala E, Teppo L, et al. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:437-9.
100. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81.
101. Krikorian JG, Burke JS, Rosenberg SA, et al. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 1979;300:452-8.
102. Boivin JF, Hutchison GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995;87:732-41.
103. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992;3(Suppl 4): 117-28.
104. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer 1993;68:1006-11.
105. Prosper F, Robledo C, Cuesta B, et al. Incidence of non-Hodgkin's lymphoma in patients treated for Hodgkin's disease. Leuk Lymphoma 1994;12:457-62.
106. Kersey JH, Spector BD, Good RA. Cancer in children with primary immunodeficiency diseases. J Pediatr 1974;84: 263-4.
107. Kersey JH, Spector BD, Good RA. Primary immunodeficiency diseases and cancer: the immunodeficiency-cancer registry. Int J Cancer 1973;12:333-47.
108. Spector BD, Perry GS III, Kersey JH. Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the immunodeficiency-cancer registry. Clin Immunol Immunopathol 1978;11:12-29.
109. Filipovich AH, Mathur A, Kamat D, et al. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992;52(19 Suppl):5465s-7s.
110. Frizzera G, Rosai J, Dehner LP, et al. Lymphoreticular disorders in primary immunodeficiencies: new findings based on an up-to-date histologic classification of 35 cases. Cancer 1980;46:692-9.
111. Primary immunodeficiency diseases: report of a WHO sponsored meeting. Immunodefic Rev 1989;1:173-205.
112. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, et al. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol 1987;7:294-9.
113. Kinlen LJ, Webster ADB, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinemia. Lancet 1985;1:263-6.
114. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986;77:89-92.
115. Zahm SH, Weisenburger DD, Cantor KP, et al. Role of the herbicide atrazine in the development of non-Hodgkin' s lymphoma. Scand J Work Environ Health 1993;19:108-14.
116. Magrath I, Jain V, Bhatia K. Epstein-Barr virus and Burkitt's lymphoma. Semin Cancer Biol 1992;3:285-95.
117. Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphoma. Cancer 1995;75(Suppl):370-80.
118. Pedersen RK, Pedersen NT. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. Histopathology 1996;28:25-32.
119. Iscovich J, Paltiel O, Azizi E, et al. Cutaneous lymphoma in Israel, 1985-1993: a population-based incidence study. Br J Cancer 1998;77:170-3.
120. Karagas MR, Thomas DB, Roth GJ, et al. The effects of changes in health care delivery on the reported incidence of ; cutaneous melanoma in western Washington State. Am J Epidemiol 1991;133:58-62.
121. Weinstock MA, Horm JW. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.
122. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 1989;81:1560-7.
123. Linet MS, McLaughlin JK, Fraumeni JF Jr, et al. Mycosis fungoides and occupation in Sweden. (Letter). J Natl Cancer Inst 1989;81:1842-3
124. d'Amore F, Johansen P, Houmand A, et al. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO. Blood 1996;87:1045-55.
125. Ott G, Ott MM, Feller AC, et al. Prevalence of Epstein-Barr virus DNA in different T-cell lymphoma entities in a European population. Int J Cancer 1992;51:562-7.
126. Anagnostopoulos I, Hummel M, Stein H. Frequent presence of latent Epstein-Barr virus infection in peripheral T cell lymphomas: a review. Leuk Lymphoma 1995;19:1-12.
127. Boiocchi M, De Re V, Gloghini A, et al. High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients. Int J Cancer 1993;54:53-9.
128. Borisch B, Caioni M, Hurwitz N, et al. Epstein-Barr virus subtype distribution in angioimmunoblastic lymphadenopathy. Int J Cancer 1993;55:748-52.
129. Madeleine MM, Wiktor SZ, Goedert JJ, et al. HTLV-I and HTLV-II world-wide distribution: reanalysis of 4,832 immunoblot results. Int J Cancer 1993;54:255-60.
130. Cleghorn FR, Manns A, Falk R, et al. Effect of human T-lymphotropic virus type 1 infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995;87:1009-14.
131. Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43:250-3.
132. Tokudome S, Tokunaga O, Shimamoto Y, et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. Cancer Res 1989;49:226-8.
133. Mueller N. The epidemiology of HTLV-I infection. Cancer Causes Control 1991;2:37-52.
134. Mueller N. Hodgkin's disease. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. New York, NY: Oxford University Press, 1996:893-919.